|
Published by: Decision Resources
Published: May. 23, 2007 - 40 Pages
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- The Breadth and Scope of Combination Products
- From a Regulatory Perspective
- Recent Biologic and Device Approvals
- Drug-and-Device Combinations Going Strong
- Strategic Use of Combination Products
- Recent Market Success of Fixed-Dose Combinations
- Fixed-Dose Combination Blockbusters
- GlaxoSmithKline’s Advair/Seretide
- AstraZeneca’s Symbicort and Boehringer Ingelheim’s Combivent
- Merck/Schering-Plough’s Vytorin/Inegy
- Novartis’s Lotrel
- HIV/AIDS Combination Blockbusters
- Antibacterial Combination Blockbusters
- Combination Blockbusters in a Contraceptive Franchise
- Significant Interest in Combination-Drug Markets
- Brand Pharmaceutical Companies
- Generics Pharmaceutical Companies
- Notable Trends
- More Timely Development of Combinations
- Intercompany Collaborations on Fixed-Dose Combinations
- Bristol-Myers Squibb and Gilead Sciences
- AstraZeneca and Abbott
- Schering-Plough and Novartis
- Multiple Combinations
- Greater Acceptance of Combination Products in Japan
- Start-Up Companies Dedicated to Combinations in Novel Indications
- CombinatoRx
- Orexi 16
- Vicus Therapeutics
- Life-Cycle Management and Market Dynamics
- Fragmented Diabetes Markets
- Thiazolidinedione Franchises
- Renaissance in NSAID Combinations Following COX-2 Inhibitor Troubles
- AstraZeneca/Pozen
- GlaxoSmithKline/Pozen
- Fixed-Dose Combination Drugs in Development
- Cardiovascular Combinations
- Pfizer’s Torcetrapib/Lipitor Combination
- Novartis’s Exforge
- Merck/Schering-Plough’s Lipitor and Zetia
- Daiichi Sankyo’s CS-8663
- Merck’s MK-0524A and MK-0524B
- Abbott’s Simcor
- Cross-Indication Combination Therapies
- Respiratory Combinations
- Schering-Plough and Novartis LABA and Corticosteroid Combinations
- Nycomed and Sanofi -Aventis’s Formoterol and Alvesco Combination
- GlaxoSmithKline and Theravance’s Promising Fixed-Dose Combinations for COPD
- Outlook
- Appendix-World’s Best-Selling Combination Products by Therapeutic Category, 2006
- Expert Commentary
- Expert Commentary: Fixed-Dose Combinations of Antiretroviral Drugs in HIV Therapy
- Regimens
- Expert Commentary: Patent Expirations and the Availability of Generic-and-Generic
- Combinations Loom Heavily Over Type 2 Diabetes Markets
- Expert Commentary: Choosing the Right Drugs for the Combination Is of Paramount
- Importance
- Expert Commentary: Opportunities for Respiratory Fixed-Dose Combinations
- Tables
- 1. Start-Up Companies Dedicated to Drug Repurposing
- 2. Summary Table: Key Opportunities and Challenges in Combination Product Development
- According to Decision Resources Experts
- Figures
- 1. Best-Selling Fixed Combination Blockbusters Worldwide, 2006
- 2. Best-Selling Combination Products by Therapeutic Category, 2006
- 3. Big Pharma’s Degree of Interest in Combination Products, 2006
- 4. Life-Cycle Management Through Fixed-Dose Combinations in Diabetes
- 2a. Fragmented Market Dynamics in Diabetes, 2000-2006
- 3a. Vytorin Enjoys Tremendous Success While Caduet Struggles
- Experts Featured
- John Earl, Ph.D., principal director, Cardium and Onkos, Decision Resources, Inc.
- Sylvia Eash, Ph.D., analyst, Infectious Diseases, Decision Resources, Inc.
- Melissa G. Stolper, director, Immune and Infl ammatory Diseases, Decision Resources, Inc.
- Mark Thornton, M.Sc., Ph.D., consultant, Decision Resources, Inc.
- Donny Wong, Ph.D., senior analyst, Metabolic Disorders, Decision Resources, Inc.
AbstractCombination products are a lifeline in today’s pharmaceutical industry, but not all are created equal. Many companies use combinations late in the product life cycle to extend patent life or to maximize revenues, but more-successful combination product development addresses a market’s unmet need. Therefore, not all potential combination products will have equal value. We asked Decision Resources analysts to share their insights on combination products in various disease markets and integrated these insights into our analysis of the combination product market in this Spectrum Special Report.
Get the Answers You Need to Shape Your Strategy
Several fi xed-dose combinations were blockbusters in 2006 while others languished. • Why do combination products fare well in some markets and not in others? Why do similar products for similar indications fare very differently in the market?
Successful combinations are sometimes a result of a single company combining its blockbuster agents, • but several intercompany collaborations on combination products have proved very successful. Which partnerships have been most successful and why? Which markets are best suited to further intercompany development?
Combination products are becoming increasingly useful in product life-cycle management. • Which combination products are in development? What do the experts think of their chances for success?
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
